Skip to main content Scroll Top

Cryoablation of the heart: Innovative cold therapy for safe cardiac rhythm treatments

Cryoablation of the heart is establishing itself as a highly safe alternative to conventional radiofrequency ablation through the targeted application of cold to ablate arrhythmogenic areas of heart tissue. This established cryotherapy technology permanently eliminates pathological electrical pathways by means of controlled hypothermia between -40°C and -80°C. This proven cryoablation of the heart offers unique safety advantages in the treatment of complex cardiac arrhythmias through reversible cryo-adhesion and has proven itself since 1998 as a curative therapy option with over 250,000 patients treated worldwide.

Medical history of cryoablation on the heart

Evolutionary development of cryotherapy

Cryoablation of the heart is based on thousands of years of knowledge about the therapeutic properties of controlled cold application, which was already used in ancient Egypt for anaesthesia and wound treatment. Modern medical cryotherapy developed in the late 19th century for targeted tissue ablation, before the first cardiac cryoablation was performed during heart surgery in 1977.

Catheter-based innovation: The breakthrough in cryoablation of the heart came in 1998 with the first successful treatment of a patient using a cryocatheter, enabling minimally invasive cold therapy without surgical intervention. This revolutionary cryoablation technology led to the development of specialised cryocatheter systems for various arrhythmia substrates, with the clinical market launch of the cryoballoon catheter for atrial fibrillation treatment in 2004.

Technological principles of cryoablation of the heart

Cryothermal ablation mechanisms

Cryoablation of the heart uses the physical principle of controlled tissue freezing by means of a liquid coolant (nitrogen dioxide), which is vaporised in specialised cryocatheters and extracts heat from the surrounding heart tissue. This targeted cryotherapy causes ice formation in the affected heart muscle cells and leads to the irreversible destruction of arrhythmogenic substrates through cell adhesion and controlled necrosis formation.

Reversible cryoadhesion advantages: A unique advantage of cardiac cryoablation is reversible tissue testing at mild temperatures around -30°C before permanent lesions are created at -60°C to -80°C. This intelligent cryoablation strategy enables preoperative functional validation and minimises the risk of unwanted cardiac arrhythmias in critical anatomical locations.

Cryoballoon technology for atrial fibrillation

Cryoballoon ablation represents the established standard application of cryoablation on the heart for pulmonary vein isolation in paroxysmal and persistent atrial fibrillation. The unique design of the cryoballoon enables:

  • Circumferential pulmonary vein isolation through anatomically conforming balloon positioning
  • Homogeneous cold distribution for complete electrical isolation
  • Reduced procedure time compared to point-by-point radiofrequency ablation
  • Minimised risk of oesophageal injury through non-thermal energy application

Clinical indications for cryoablation of the heart

Supraventricular arrhythmia treatment

Cryoablation of the heart is highly effective in treating cardiac arrhythmias near the AV node, particularly AV nodal reentry tachycardia (AVNRT), where reversible cryoadhesion minimises the risk of permanent AV block. This safe cryoablation application significantly reduces the likelihood of pacemaker dependency compared to thermal ablation procedures.

Treatment of atrial fibrillation: In paroxysmal atrial fibrillation, cryoballoon ablation achieves comparable long-term success rates to radiofrequency ablation, with 70-80% one-year success rates and improved patient tolerance. The FIRE AND ICE study *1 documented the non-inferiority of cryoablation on the heart compared to conventional point-by-point ablation, with reduced re-ablation rates and hospitalisations.

Extended cryoablation indications

Ventricular tachycardia therapy: Innovative vCLAS cryoablation systems enable the treatment of complex ventricular tachycardias in structural heart disease by using ultra-low temperatures to freeze pre-damaged heart muscle. This advanced cryoablation technology treats scar-related arrhythmias with lesion sizes greater than 10 mm in diameter for deep substrate modification.

Safety profile and complication prevention

Superior safety features

Cryoablation of the heart has an optimised safety profile due to its non-thermal properties:

Specific safety advantages:

  • Pain-free procedure thanks to cryothermal local anaesthesia
  • Reduced thrombogenicity with cold application
  • Minimal risk of oesophageal injury during posterior atrial ablation
  • Protection of the phrenic nerve through continuous stimulation monitoring

AV node protection: For ablations near the AV node, cryoablation of the heart shows significantly lower rates of permanent AV block compared to radiofrequency ablation, minimising the need for permanent pacemaker implantation.

Modern cryoablation systems and innovation

Next-generation cryotechnology

Contemporary cryoablation systems integrate intelligent temperature control, adaptive catheter design and advanced monitoring capabilities for optimised procedural safety. Novel fourth-generation cryoballoons enable improved signal control from pulmonary veins during cryoablation for patient-specific therapy adjustment.

3D navigation integration: Cryoablation of the heart benefits from electroanatomical mapping systems with real-time catheter visualisation and CT/MRI fusion for precise anatomical navigation with reduced fluoroscopy time and optimised radiation exposure.

Evidence-based long-term results

Landmark studies on cryoablation of the heart

Another study (Cryo First Study by Medtronic) demonstrated the superiority of cryoballoon catheter ablation over antiarrhythmic pharmacotherapy in first-line treatment, with significantly improved rhythm stabilisation and symptom control. The MANIFEST-17K registry, with over 17,000 patients, documented a 73% one-year success rate in paroxysmal atrial fibrillation with <1% major complication rates.

Real-world evidence: Over 250,000 patients worldwide treated with cryoballoon technology demonstrate the excellent safety and effectiveness of cryoablation on the heart in various patient populations with continuously improved technological systems.

High-precision EP systems for optimised cryoablation of the heart

The therapeutic excellence of cryoablation on the heart requires integrated electrophysiological measurement systems with high-resolution 3D mapping, precise temperature monitoring and advanced cryo-adhesion monitoring functions. Modern EP platforms with intelligent cryoablation integration enable the successful performance of complex cryothermal cardiac rhythm interventions with maximum procedural safety and sustainable curative treatment results through exceptional anatomical visualisation, real-time lesion quality assessment and automated temperature control.

 

*1 The FIRE AND ICE study is one of the largest multicentre, controlled studies investigating the effectiveness and safety of pulmonary vein isolation with cryoballoon catheters compared to radiofrequency catheter therapy in patients with paroxysmal atrial fibrillation.

 

Note: This information is intended for medical training purposes only and does not replace specialist advice from qualified interventional electrophysiologists. Performing cryoablation on the heart requires specialised training and appropriate certification in invasive electrophysiology.